281 related articles for article (PubMed ID: 34036238)
1.
Socinski MA; Pennell NA; Davies KD
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036238
[No Abstract] [Full Text] [Related]
2. MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis.
Lambros L; Uguen A
Clin Lung Cancer; 2019 May; 20(3):e418-e420. PubMed ID: 30606657
[No Abstract] [Full Text] [Related]
3. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
[TBL] [Abstract][Full Text] [Related]
4. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
Yin L; Lu Y
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
[TBL] [Abstract][Full Text] [Related]
5. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
6. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
[TBL] [Abstract][Full Text] [Related]
7. MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
Drilon A
Clin Cancer Res; 2016 Jun; 22(12):2832-4. PubMed ID: 27009743
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With
Hur JY; Ku BM; Shim JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
In Vivo; 2020; 34(3):1399-1406. PubMed ID: 32354937
[TBL] [Abstract][Full Text] [Related]
9. Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
Shi M; Ma J; Feng M; Liang L; Chen H; Wang T; Xie Z
Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
11. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
12. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
[TBL] [Abstract][Full Text] [Related]
13. Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.
Awad MM
J Clin Oncol; 2016 Mar; 34(8):879-81. PubMed ID: 26786927
[No Abstract] [Full Text] [Related]
14. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
[No Abstract] [Full Text] [Related]
15. Prevalence of
Yu Y; Zhang Q; Zhang J; Lu S
J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
[TBL] [Abstract][Full Text] [Related]
16. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
17. Molecular cytopathology diagnosis of a lung neoplasm: Case report of an unusual non-small cell carcinoma with MET exon 14 skipping mutation.
Hosseini SM; Khanafshar E; Seeley EJ; Ruiz-Cordero R
Diagn Cytopathol; 2021 Jul; 49(7):E258-E261. PubMed ID: 33433963
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Baba K; Tanaka H; Sakamoto H; Shiratori T; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Tasaka S
Thorac Cancer; 2019 Feb; 10(2):369-372. PubMed ID: 30600919
[TBL] [Abstract][Full Text] [Related]
19. [MET exon 14 mutation, new target in lung sarcomatoid carcinoma].
Domblides C; Cortot A; Wislez M
Bull Cancer; 2015 Dec; 102(12):966. PubMed ID: 27064153
[No Abstract] [Full Text] [Related]
20. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
